UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Amendment No. 3)

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934

China Biologic Products Holdings, Inc.

(Name of issuer)

Ordinary Shares, par value US$0.0001 per share

(Title of class of securities)

G21515104 ⁽¹⁾

(CUSIP number)

Joseph Chow
Chief Executive Officer

18th Floor, Jialong International Building, 19 Chaoyang Park Road

Chaoyang District, Beijing 100125

People’s Republic of China
Tel: +86 (10) 6598-3111

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 28, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

⁽¹⁾ This CUSIP number applies to the Issuer’s Ordinary Shares.

(1) Includes 358,333 Ordinary Shares that Double Double has agreed to sell to BDL pursuant to the BDL SPA.
* Calculation is based upon 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 provided by the Issuer.

* Calculation is based upon 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 provided by the Issuer.

(1) Includes 358,333 Ordinary Shares that Double Double has agreed to sell to BDL pursuant to the BDL SPA.

(2) Includes (i) 11,509 Ordinary Shares directly held by Mr. Chow and 42,750 Ordinary Shares issuable upon exercise of restricted share units held by Mr. Chow within 60 days from the day hereof; and (ii) 1,435,833 Ordinary Shares deemed to be beneficially owned by Mr. Chow through BDL and BFL (including 358,333 Ordinary Shares that Double Double has agreed to sell to BDL pursuant to the BDL SPA).

* Calculation is based upon 38,788,096 Ordinary Shares issued and outstanding as of December 18, 2020 provided by the Issuer.

Item 1. Security and Issuer.

This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) amends and supplements the statement on Schedule 13D filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 23, 2020, as amended by Amendment No. 1 filed on October 29, 2020 and Amendment No. 2 filed on November 20, 2020 (the “Schedule 13D”) with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of China Biologic Products Holdings, Inc., a Cayman Islands exempted company (the “Issuer”) whose principal executive offices is 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing 100125, People’s Republic of China.

The Issuer’s Ordinary Shares are listed on the NASDAQ Global Select Market under the symbol “CBPO”.

Except as provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms used but not defined in this Amendment No.3 have the means ascribed to them in the Schedule 13D.

Item 2. Identity and Background.

Item 2 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

This Amendment No. 3 is being jointly filed by the following persons pursuant to Rule 13d-1(k) promulgated under the Act:

(1)       Biomedical Development Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“BDL”);

(2)       Biomedical Future Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“BFL”); and

(3)       Mr. Joseph Chow (“Mr. Chow”, and together with BDL and BFL, the “Reporting Persons”), a citizen of the United States, (i) the Chairman of the board of directors of the Issuer, (ii) the Chief Executive Officer of the Issuer, and (iii) the sole director of each of BDL and BFL.

The principal business of each of BDL and BFL is investment holding. The business address of each Reporting Person is 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing 100125, People’s Republic of China.

None of the Reporting Persons has, during the last five years, been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or subject to any judgment, decree or final order finding any violation of federal or state securities laws or enjoining future violations of, or prohibiting or mandating activities subject to, such laws.

Item 4. Purpose of the Transaction.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

On December 28, 2020, BDL completed the first closing of the purchase of 416,667 Ordinary Shares from Double Double pursuant to the terms and conditions of the BDL SPA and expects to complete the second closing of the purchase of 358,333 Ordinary Shares from Double Double in early January 2021.

On December 30, 2020, BFL completed the purchase of 660,833 Oridnary Shares from PWM pursuant to the terms and conditions of the BFL SPA.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

(a)-(b)        Items 7 through 11 and 13 (including the footnotes thereto) of each of the cover pages of this Schedule 13D are incorporated by reference into this Item 5.

Because of the arrangements in the A&R Consortium Agreement, the parties to that agreement are deemed to have formed a “group” for purposes of Section 13(d)(3) of the Act, and such “group” is deemed to beneficially own an aggregate of 26,528,890 Ordinary Shares, which represents approximately 68.3% of the total number of Ordinary Shares issued and outstanding as of December 18, 2020 as provided by the Issuer. Neither the filing of this Amendment No. 3 nor any of its contents, however, shall be deemed to constitute an admission by the Reporting Persons that any of them is the beneficial owner of any of the 25,038,798 Ordinary Shares beneficially owned in the aggregate by Centurium, PWM, Parfield, CITIC Capital, Hillhouse, V-Sciences and their respective affiliates for purposes of Section 13(d) of the Act or for any other purpose, and such beneficial ownership is expressly disclaimed.

(c)        Except as set forth herein, to the knowledge of the Reporting Person with respect to the persons named in response to Item 5(a)-(b), none of the person named in response to Item 5(a)-(b) has effected any transactions in the Ordinary Shares during the past 60 days.

(d)        No person other than the persons listed is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities owned by the Reporting Person.

(e)        Not applicable.

Item 7. Material to be Filed as Exhibits.

Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: December 31, 2020